14-day Premium Trial Subscription Sign Up For FreeGet Free

When Should You SELL Your Stocks? Click to watch.

ACADIA Pharmaceuticals Inc. Stock Forecast

NASDAQ:ACAD BUY SELL

$16.83 (4.93%)

Volume: 1.628M

Closed: May 19, 2022

Hollow Logo Score: -2.140

ACADIA Pharmaceuticals Inc. Stock Forecast

BUY SELL NASDAQ:ACAD
$16.83 (4.93%)

Volume: 1.628M

Closed: May 19, 2022

Score Hollow Logo -2.140

ACADIA Pharmaceuticals Inc. Stock Forecast NASDAQ:ACAD

Price Target and Analyst Ratings

Historical Ratings

Date Upside / Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
2022-04-19 60.43% Mizuho $28.00 $27.00 Maintains Neutral
2022-03-16 84.19% Canaccord Genuity $30.00 $31.00 Upgrades Hold Buy
2022-03-10 119.85% Cantor Fitzgerald $32.00 $37.00 Maintains Overweight
2022-03-07 42.6% Goldman Sachs $27.00 $24.00 Maintains Neutral
2022-03-03 66.37% Mizuho $33.00 $28.00 Maintains Neutral
2022-03-01 107.96% JMP Securities $42.00 $35.00 Maintains Market Outperform
2022-02-09 113.9% HC Wainwright & Co. $18.00 $36.00 Upgrades Neutral Buy
2022-01-05 78.25% Citigroup $30.00 Upgrades Neutral Buy
2021-12-22 78.25% Canaccord Genuity $26.00 $30.00 Maintains Hold
2021-12-21 149.55% JMP Securities $39.00 $42.00 Maintains Market Outperform
2021-12-21 90.14% B of A Securities $28.00 $32.00 Maintains Neutral
2021-12-21 66.37% Guggenheim $28.00 Downgrades Buy Neutral
2021-12-21 102.02% RBC Capital $32.00 $34.00 Maintains Outperform
2021-12-21 78.25% Citigroup $28.00 $30.00 Maintains Neutral
2021-12-09 36.66% Oppenheimer $20.00 $23.00 Maintains Perform
2021-12-09 131.73% JMP Securities $35.00 $39.00 Maintains Market Outperform
2021-12-08 66.37% Goldman Sachs $25.00 $28.00 Maintains Neutral
2021-12-07 66.37% Citigroup $25.00 $28.00 Maintains Neutral
2021-12-07 131.73% JMP Securities $35.00 $39.00 Maintains Market Outperform
2021-12-07 54.49% Mizuho $24.00 $26.00 Maintains Neutral
2021-12-07 42.6% Morgan Stanley $21.00 $24.00 Maintains Equal-Weight
2021-12-07 36.66% Oppenheimer $20.00 $23.00 Maintains Perform
2021-11-01 36.66% Guggenheim $23.00 Upgrades Neutral Buy
2021-10-14 18.84% Morgan Stanley $20.00 Downgrades Overweight Equal-Weight
2021-08-05 66.37% SVB Leerink $31.00 $28.00 Maintains Outperform
2021-08-05 60.43% Morgan Stanley $29.00 $27.00 Maintains Overweight
2021-08-05 54.49% Needham $30.00 $26.00 Maintains Buy
2021-06-10 72.31% Berenberg $29.00 Initiates Coverage On Hold
2021-05-12 60.43% Canaccord Genuity $26.00 $27.00 Maintains Hold
2021-05-06 72.31% Morgan Stanley $28.00 $29.00 Maintains Overweight
2021-04-07 6.95% HC Wainwright & Co. $43.00 $18.00 Downgrades Buy Neutral
2021-04-06 66.37% Morgan Stanley $50.00 $28.00 Maintains Overweight
2021-04-06 48.54% Goldman Sachs $73.00 $25.00 Downgrades Buy Neutral
2021-04-06 48.54% Mizuho $25.00 Downgrades Buy Neutral
2021-04-06 54.49% Canaccord Genuity $40.00 $26.00 Downgrades Buy Hold
2021-04-06 24.78% Jefferies $40.00 $21.00 Downgrades Buy Hold
2021-04-05 78.25% Needham $44.00 $30.00 Maintains Buy
2021-03-10 - B of A Securities - Downgrades Buy Neutral
2021-03-09 - Guggenheim - Downgrades Buy Neutral
2021-03-09 60.43% Stifel $68.00 $27.00 Downgrades Buy Hold
2021-03-09 161.44% Needham $60.00 $44.00 Maintains Buy
2021-03-09 137.67% Canaccord Genuity $61.00 $40.00 Maintains Buy
2021-03-09 197.09% Morgan Stanley $65.00 $50.00 Maintains Overweight
2021-03-09 155.5% HC Wainwright & Co. $60.00 $43.00 Maintains Buy
2021-03-09 107.96% Citigroup $66.00 $35.00 Downgrades Buy Neutral
2021-03-09 107.96% Raymond James $65.00 $35.00 Downgrades Strong Buy Outperform
2021-02-25 286.22% Morgan Stanley $60.00 $65.00 Maintains Overweight
2020-12-16 256.51% Morgan Stanley $58.00 $60.00 Maintains Overweight
2020-12-16 309.98% Mizuho $69.00 Initiates Coverage On Buy
2020-11-16 286.22% Raymond James $65.00 Upgrades Outperform Strong Buy
2020-11-05 244.62% Morgan Stanley $57.00 $58.00 Maintains Overweight
2020-10-13 238.68% Morgan Stanley $55.00 $57.00 Maintains Overweight
2020-08-25 286.22% Raymond James $65.00 Initiates Coverage On Outperform
2020-08-20 226.8% Morgan Stanley $55.00 Initiates Coverage On Overweight
2020-08-06 256.51% Canaccord Genuity $56.00 $60.00 Maintains Buy
2020-08-06 208.97% SVB Leerink $56.00 $52.00 Maintains Outperform
2020-07-21 149.55% Oppenheimer $53.00 $42.00 Maintains Perform
2020-07-21 262.45% Cantor Fitzgerald $63.00 $61.00 Maintains Overweight
2020-07-21 226.8% RBC Capital $61.00 $55.00 Maintains Outperform
2020-07-07 321.87% Stifel $41.00 $71.00 Upgrades Hold Buy
2020-05-27 214.91% Oppenheimer $48.00 $53.00 Maintains Perform
2020-05-08 226.8% JP Morgan $50.00 $55.00 Maintains Overweight
2020-05-08 274.33% Cantor Fitzgerald $58.00 $63.00 Reiterates Overweight
2020-04-16 256.51% Jefferies $60.00 Initiates Coverage On Buy
2020-03-31 327.81% Goldman Sachs $45.00 $72.00 Upgrades Neutral Buy
2020-03-06 309.98% Citigroup $69.00 Initiates Coverage On Buy
2020-03-02 96.08% JP Morgan $35.00 $33.00 Maintains Neutral
2020-02-27 345.63% Cantor Fitzgerald $70.00 $75.00 Reiterates Overweight
2019-12-16 256.51% Guggenheim $60.00 Initiates Coverage On Buy
2019-11-26 315.92% Cantor Fitzgerald $63.00 $70.00 Reiterates Overweight
2019-11-07 107.96% JP Morgan $33.00 $35.00 Maintains Neutral
2019-10-24 161.44% Oppenheimer $44.00 Initiates Coverage On Perform
2019-10-01 256.51% RBC Capital $60.00 Initiates Coverage On Outperform
2019-09-23 232.74% Cantor Fitzgerald $49.00 $56.00 Maintains Overweight
2019-09-13 197.09% SVB Leerink $21.00 $50.00 Upgrades Market Perform Outperform
2019-09-10 - Canaccord Genuity - Upgrades Hold Buy
2019-09-09 256.51% Needham $34.00 $60.00 Maintains Buy
2019-09-03 66.37% Stifel $24.00 $28.00 Maintains Hold
2019-08-27 137.67% Cantor Fitzgerald $30.00 $40.00 Reiterates Overweight
2019-05-31 155.5% Raymond James $40.00 $43.00 Reiterates Strong Buy

ACAD Stock Trend

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled.

Given the current short-term trend, the stock is expected to fall -30.01% during the next 3 months and, with a 90% probability hold a price between $10.04 and $15.73 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Data

Date Bottom Mid Top
2022-05-23 $14.18 $18.25 $22.32
2022-05-24 $14.03 $18.09 $22.16
2022-05-25 $13.87 $17.94 $22.00
2022-05-26 $13.71 $17.78 $21.85
2022-05-27 $13.55 $17.62 $21.69
2022-05-31 $13.39 $17.46 $21.53
2022-06-01 $13.24 $17.30 $21.37
2022-06-02 $13.08 $17.15 $21.21
2022-06-03 $12.92 $16.99 $21.06
2022-06-06 $12.76 $16.83 $20.90
2022-06-07 $12.60 $16.67 $20.74
2022-06-08 $12.45 $16.51 $20.58
2022-06-09 $12.29 $16.36 $20.42
2022-06-10 $12.13 $16.20 $20.27
2022-06-13 $11.97 $16.04 $20.11
2022-06-14 $11.81 $15.88 $19.95
2022-06-15 $11.66 $15.72 $19.79
2022-06-16 $11.50 $15.57 $19.63
2022-06-17 $11.34 $15.41 $19.48
2022-06-21 $11.18 $15.25 $19.32
2022-06-22 $11.02 $15.09 $19.16
2022-06-23 $10.86 $14.93 $19.00
2022-06-24 $10.71 $14.78 $18.84
2022-06-27 $10.55 $14.62 $18.69
2022-06-28 $10.39 $14.46 $18.53
2022-06-29 $10.23 $14.30 $18.37
2022-06-30 $10.07 $14.14 $18.21
2022-07-01 $9.92 $13.99 $18.05
2022-07-05 $9.76 $13.83 $17.90
2022-07-06 $9.60 $13.67 $17.74

About ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Its lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinson’s disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of Alzh... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!
.

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT